Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE, Matrana MR, Burkard ME, Yang ES, Edenfield WJ, Dees EC, Onitilo AA, Thompson M, Buchschacher GL Jr, Miller AM, Menter A, Parsons B, Wassenaar T, Hwang LC, Suga JM, Siegel R, Irvin W Jr, Nair S, Slim JN, Misleh J, Khatri J, Masters G, Thomas S, Safa M, Anderson DM, Kwiatkowski K, Mitchell K, Hu-Seliger T, Drewery S, Fischer A, Plouffe K, Czuprenski E, Hipp J, Reeder T, Vakil H, Johnson DB, Rhodes DR. Tomlins SA, et al. Among authors: matrana mr. Commun Med (Lond). 2023 Feb 7;3(1):14. doi: 10.1038/s43856-023-00243-7. Commun Med (Lond). 2023. PMID: 36750617 Free PMC article.
Neuroendocrine tumors of the kidney: a single institution experience.
Teegavarapu PS, Rao P, Matrana M, Cauley DH, Wood CG, Tannir NM. Teegavarapu PS, et al. Clin Genitourin Cancer. 2014 Dec;12(6):422-7. doi: 10.1016/j.clgc.2014.06.008. Epub 2014 Jun 11. Clin Genitourin Cancer. 2014. PMID: 25088468 Free PMC article.
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. Piva F, et al. Among authors: matrana mr. Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Tomlins SA, Hovelson DH, Suga JM, Anderson DM, Koh HA, Dees EC, McNulty B, Burkard ME, Guarino M, Khatri J, Safa MM, Matrana MR, Yang ES, Menter AR, Parsons BM, Slim JN, Thompson MA, Hwang L, Edenfield WJ, Nair S, Onitilo A, Siegel R, Miller A, Wassenaar T, Irvin WJ, Schulz W, Padmanabhan A, Harish V, Gonzalez A, Mansoor AH, Kellum A, Harms P, Drewery S, Falkner J, Fischer A, Hipp J, Kwiatkowski K, Lazo de la Vega L, Mitchell K, Reeder T, Siddiqui J, Vakil H, Johnson DB, Rhodes DR. Tomlins SA, et al. Among authors: matrana mr. JCO Precis Oncol. 2021 Aug 19;5:PO.20.00472. doi: 10.1200/PO.20.00472. eCollection 2021 Aug. JCO Precis Oncol. 2021. PMID: 34476329 Free PMC article.
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. Patel SP, et al. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969335 Free PMC article. Clinical Trial.
72 results